The Effect of a Natural Polyphenolic Extract From Pomegrnate (POMX) on the Development of Atherosclerosis in Diabetic Patients

This study is not yet open for participant recruitment.

Verified by HaEmek Medical Center, Israel, April 2007

First Received: May 7, 2007 No Changes Posted

Sponsored by:	HaEmek Medical Center, Israel
Information provided by:	HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier:	NCT00470808

Purpose

Diabetes is a highly atherogenic disease. Pomegranate juice has impressive antioxidant properties. It has been proven to decrease oxidant stress and to cause the regression of atherosclerotic plaques in hypercholestrolemic and diabetic patients.Furthermore it has been proven to potentiate the biologic activity of the enzyme paraoxonase 1 which is very important in preventing atherosclerosis. The study will try to prove that a polyphenolic extract from pomegranate (POMx) has the same desired effects.

Condition	Intervention	Phase
Atherosclerosis	Drug: POMx	Phase IV

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study

Further study details as provided by HaEmek Medical Center, Israel:

Study Start Date:	May 2007
Estimated Study Completion Date:	August 2007

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Males
HBA1C>7%
Drug therapy given for DM

Exclusion Criteria:

Age<18
Inclusion in another study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00470808

Contacts

Contact: Wasseem Rock, MD

0547866896

wasseem_rock@yahoo.com

Locations

Israel
Ha'Emek Medical Center
Afula, Israel, 18101

Sponsors and Collaborators

HaEmek Medical Center, Israel

Investigators

Principal Investigator:

Wasseem Rock, MD

Ha'emek Medical Center

More Information

No publications provided

Study ID Numbers:	0051-07-EMC
Study First Received:	May 7, 2007
Last Updated:	May 7, 2007
ClinicalTrials.gov Identifier:	NCT00470808 History of Changes
Health Authority:	Israel: Ministry of Health

Keywords provided by HaEmek Medical Center, Israel:

Minors
Enrollment in another study
Males
HBA1C greater than 7
Drug therapy for DM

Study placed in the following topic categories:

Arterial Occlusive Diseases
Atherosclerosis
Vascular Diseases
Arteriosclerosis

Additional relevant MeSH terms:

Arterial Occlusive Diseases
Atherosclerosis
Vascular Diseases
Cardiovascular Diseases
Arteriosclerosis

ClinicalTrials.gov processed this record on May 07, 2009